Novo Nordisk women's health products
Novo and Rhone-Poulenc Rorer have decided to terminate their worldwide hormone replacement therapy copromotion agreement, Novo announces. The agreement "has so far resulted in local cooperation in several countries," Novo says, but "the parties have agreed that the potential for establishing further local agreements have been exhausted." The first product to be copromoted in the U.S. was to be Novo's oral estradiol tablet Estrofem (Innofem in the U.S.). An ANDA for Innofem, equivalent to Bristol-Myers Squibb's Estrace, was filed April 30. Novo also disclosed that an NDA for Vagifem (25 mcg estradiol vaginal tablet) was submitted to FDA May 28 for treatment of atrophic vaginitis
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth